Karuna Therapeutics
Clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions.
Launch date
Employees
Market cap
AUD19.5b
Enterprise valuation
AUD17.5b (Public information from Mar 2024)
Share price
$329.82999 KRTX
Boston Massachusetts (HQ)
Financials
Estimates*
| USD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 10.6m | 10.6m | - | - | 37.0m | 10.6m | <1m |
| % growth | - | - | - | - | - | (71 %) | (94 %) |
| EBITDA | (4.9m) | (14.9m) | (42.9m) | (68.5m) | (143m) | (290m) | (493m) |
| % EBITDA margin | (46 %) | (140 %) | - | - | (387 %) | (2723 %) | (75394 %) |
| Profit | (6.0m) | (17.5m) | (44.0m) | (68.6m) | (144m) | (276m) | (434m) |
| % profit margin | (57 %) | (165 %) | - | - | (389 %) | (2598 %) | (66312 %) |
| R&D budget | 3.6m | 11.5m | 24.5m | 43.4m | 128m | 224m | 364m |
| R&D % of revenue | 34 % | 108 % | - | - | 347 % | 2108 % | 55673 % |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | $600k | Debt | |
$8.0m | Grant | ||
* | $42.0m | Series A | |
$68.0m | Series B | ||
| N/A | N/A | IPO | |
* | N/A | $250m | Post IPO Equity |
* | N/A | $100m | POST IPO SECONDARY |
* | N/A | $750m | Post IPO Equity |
* | N/A | $460m | Post IPO Equity |
* | $14.0b Valuation: $14.0b 1316.2x EV/LTM Revenues -48.3x EV/LTM EBITDA | Acquisition | |
| Total Funding | AUD182m | ||
Recent News about Karuna Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.